Sonoclot analysis in healthy children

Evan G. Pivalizza, Penelope J. Pivalizza, Spencer Kee, Lewis I. Gottschalk, Peter Szmuk, David C. Abramson

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although use of the Sonoclot device (Sienco, Inc., Morrison, CO) has been reported in isolated pediatric cases and in small reports in neonates, there are no published data for normal pediatric patients. As the device is used in situations of abnormal coagulation, such as cardiac and liver transplantation surgery, our aim was to determine normal data ranges in healthy pediatric surgical patients. Blood was withdrawn after anesthetic induction, and the Sonoclot activated clotting time, rate of clot formation, time to peak amplitude, and peak amplitude was compared among four pediatric groups (< 12 mo, 13-24 mo, 25-48 mo, 49 mo-9 yr) and an adult group. The Sonoclot activated clotting time in the < 12-mo and the Adult groups were shorter than the oldest group of children (P < 0.05), although all were within the anticipated normal range, and there were no significant differences in clot rate, peak amplitude, and time to peak amplitude among groups without apparent trends with increasing age. These Sonoclot variables quantify adequate global clot formation in pediatric patients and will facilitate clinical coagulation management with appropriate pediatric normal ranges, avoiding the application of extrapolated adult data to children.

Original languageEnglish (US)
Pages (from-to)904-906
Number of pages3
JournalAnesthesia and Analgesia
Volume92
Issue number4
StatePublished - 2001

Fingerprint

Pediatrics
Reference Values
Equipment and Supplies
Heart Transplantation
Carbon Monoxide
Liver Transplantation
Anesthetics
Newborn Infant

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Pivalizza, E. G., Pivalizza, P. J., Kee, S., Gottschalk, L. I., Szmuk, P., & Abramson, D. C. (2001). Sonoclot analysis in healthy children. Anesthesia and Analgesia, 92(4), 904-906.

Sonoclot analysis in healthy children. / Pivalizza, Evan G.; Pivalizza, Penelope J.; Kee, Spencer; Gottschalk, Lewis I.; Szmuk, Peter; Abramson, David C.

In: Anesthesia and Analgesia, Vol. 92, No. 4, 2001, p. 904-906.

Research output: Contribution to journalArticle

Pivalizza, EG, Pivalizza, PJ, Kee, S, Gottschalk, LI, Szmuk, P & Abramson, DC 2001, 'Sonoclot analysis in healthy children', Anesthesia and Analgesia, vol. 92, no. 4, pp. 904-906.
Pivalizza EG, Pivalizza PJ, Kee S, Gottschalk LI, Szmuk P, Abramson DC. Sonoclot analysis in healthy children. Anesthesia and Analgesia. 2001;92(4):904-906.
Pivalizza, Evan G. ; Pivalizza, Penelope J. ; Kee, Spencer ; Gottschalk, Lewis I. ; Szmuk, Peter ; Abramson, David C. / Sonoclot analysis in healthy children. In: Anesthesia and Analgesia. 2001 ; Vol. 92, No. 4. pp. 904-906.
@article{9a52522d177540c7a59e2f0ac646468c,
title = "Sonoclot analysis in healthy children",
abstract = "Although use of the Sonoclot device (Sienco, Inc., Morrison, CO) has been reported in isolated pediatric cases and in small reports in neonates, there are no published data for normal pediatric patients. As the device is used in situations of abnormal coagulation, such as cardiac and liver transplantation surgery, our aim was to determine normal data ranges in healthy pediatric surgical patients. Blood was withdrawn after anesthetic induction, and the Sonoclot activated clotting time, rate of clot formation, time to peak amplitude, and peak amplitude was compared among four pediatric groups (< 12 mo, 13-24 mo, 25-48 mo, 49 mo-9 yr) and an adult group. The Sonoclot activated clotting time in the < 12-mo and the Adult groups were shorter than the oldest group of children (P < 0.05), although all were within the anticipated normal range, and there were no significant differences in clot rate, peak amplitude, and time to peak amplitude among groups without apparent trends with increasing age. These Sonoclot variables quantify adequate global clot formation in pediatric patients and will facilitate clinical coagulation management with appropriate pediatric normal ranges, avoiding the application of extrapolated adult data to children.",
author = "Pivalizza, {Evan G.} and Pivalizza, {Penelope J.} and Spencer Kee and Gottschalk, {Lewis I.} and Peter Szmuk and Abramson, {David C.}",
year = "2001",
language = "English (US)",
volume = "92",
pages = "904--906",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Sonoclot analysis in healthy children

AU - Pivalizza, Evan G.

AU - Pivalizza, Penelope J.

AU - Kee, Spencer

AU - Gottschalk, Lewis I.

AU - Szmuk, Peter

AU - Abramson, David C.

PY - 2001

Y1 - 2001

N2 - Although use of the Sonoclot device (Sienco, Inc., Morrison, CO) has been reported in isolated pediatric cases and in small reports in neonates, there are no published data for normal pediatric patients. As the device is used in situations of abnormal coagulation, such as cardiac and liver transplantation surgery, our aim was to determine normal data ranges in healthy pediatric surgical patients. Blood was withdrawn after anesthetic induction, and the Sonoclot activated clotting time, rate of clot formation, time to peak amplitude, and peak amplitude was compared among four pediatric groups (< 12 mo, 13-24 mo, 25-48 mo, 49 mo-9 yr) and an adult group. The Sonoclot activated clotting time in the < 12-mo and the Adult groups were shorter than the oldest group of children (P < 0.05), although all were within the anticipated normal range, and there were no significant differences in clot rate, peak amplitude, and time to peak amplitude among groups without apparent trends with increasing age. These Sonoclot variables quantify adequate global clot formation in pediatric patients and will facilitate clinical coagulation management with appropriate pediatric normal ranges, avoiding the application of extrapolated adult data to children.

AB - Although use of the Sonoclot device (Sienco, Inc., Morrison, CO) has been reported in isolated pediatric cases and in small reports in neonates, there are no published data for normal pediatric patients. As the device is used in situations of abnormal coagulation, such as cardiac and liver transplantation surgery, our aim was to determine normal data ranges in healthy pediatric surgical patients. Blood was withdrawn after anesthetic induction, and the Sonoclot activated clotting time, rate of clot formation, time to peak amplitude, and peak amplitude was compared among four pediatric groups (< 12 mo, 13-24 mo, 25-48 mo, 49 mo-9 yr) and an adult group. The Sonoclot activated clotting time in the < 12-mo and the Adult groups were shorter than the oldest group of children (P < 0.05), although all were within the anticipated normal range, and there were no significant differences in clot rate, peak amplitude, and time to peak amplitude among groups without apparent trends with increasing age. These Sonoclot variables quantify adequate global clot formation in pediatric patients and will facilitate clinical coagulation management with appropriate pediatric normal ranges, avoiding the application of extrapolated adult data to children.

UR - http://www.scopus.com/inward/record.url?scp=0035080336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035080336&partnerID=8YFLogxK

M3 - Article

C2 - 11273922

AN - SCOPUS:0035080336

VL - 92

SP - 904

EP - 906

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 4

ER -